Widespread commercial evaluation experience spanning multiple therapy areas for biotherapeutics and small molecules; assessments of drug opportunities in specialty care, primary care & those with orphan drug designation; biologic platforms & technologies.
To date, Atebion BDS have experience of conducting evaluations in the following areas
Atebion has conducted work in the following areas:
Atebion has provided advice and guidance on the development of - and target selection for - novel platforms for optimised drug discovery & selection
We have provided services including business development leadership & support,
Investment sourcing and Target selection & prioritisation
Atebion has advised on development path for companies with novel small molecules and biotherapeutics
We have developed plans by stage; from pre-nomination to late clinical
We have worked within mainstream & Orphan indications across multiple therapy areas, providing Target Product Profiles, market landscaping, competitor analysis and pipeline reviews
Atebion has expertise in small and large molecule development. We have provided services across multiple therapy areas for mainstream and Orphan diseases, as well as advising groups with enabling platform technologies.
We have advised companies with novel drug discovery approaches and early-stage compounds, providing drug development pathways by stage, from Pre-nomination and lead generation to late clinical development; highlighting key Investment Decision Milestones & inflexion points
Services have included product profiling, raising investment & Business Development
Within Biotherapeutics, Atebion’s projects have included antibodies, proteins & enzymes, antibody fragments & link proteins, cell line optimization platforms, Process development strategies
Atebion has provided advice, guidance, BD and investment support to companies with technologies relating to biotherapeutics and small molecules, including;
We have provided commercial feasibility assessments, investment & BD support and technology development pathways
Atebion has provided guidance on the development and marketing of smart technologies for improved disease characterisation, tools for fast & accurate patient assessment, point of care diagnostics and novel analytic technologies
We have provided commercial feasibility assessments, BD guidance & support and investment support
Atebion has provided support and guidance for a wide range of projects for Orphan diseases, including;
We have worked on programmes across multiple therapy areas including Oncology, Immunology, Inflammation, CNS, Ophthalmic, Cardiometabolics, Endocrinology and Respiratory.
We have provided development pathways, commercialization plans & strategies, market landscaping & forecasts, S&M infrastructure & costs
We have experience of patient sub-populations for adults, paediatrics, infants & pre-terms
Atebion has worked on drug development & medical device programmes for younger populations, including new-borns, infants and paediatrics.
We have provided development pathways and offered guidance on regulatory pathways and commercialization approaches
We have provided asset development programmes & market landscaping, commercialization routes, BD & investment support for companies with novel drugs, as well as re-formulations of existing drugs for mainstream and Orphan indications
Atebion regularly provides commercialization feasibility advice for research groups with early stage assets looking to spin-out companies. We also provide ‘preparation for launch’ and launch programmes for companies looking to commercialise late-stage assets, especially within Orphan diseases.
We have worked across multiple therapy areas with small molecules (including with devices) & biotherapeutics
Atebion has provided programmes and guidance which span multiple Regions, (Europe, US, Japan, Asia Pacific) as well as for individual markets
We provide Sales & Marketing infrastructure resource and associated cost estimates, A&P programmes, PhIV development programmes, with full P&L analyses and Board presentations as required
Atebion has provided advice and guidance on compounds and technologies that have potential utility in the growing nutraceutical sector, for BioTech and Major Pharma.
We have provided commercial feasibility reports, development pathways including pricing structures across World Regions, BD support and market forecasts
Atebion offers considerable expertise in defining plans, trouble-shooting and defining process requirements for biotherapeutics including;
Atebion has provided BD and investment support to companies with early-stage assets for animal health indications, advising on development & regulatory pathways and providing relevant materials for Licensees and investors